Mice of the Sl/Sld genotype have an approximately 3-fold higher number of fibroblastoid progenitors (CFU-F) in their spleens than their normal +/+ littermates. Experiments were performed to determine whether the elevated Sl/Sld splenic CFU-F numbers were due to compensatory mechanisms acting in the presence of a functionally abnormal CFU-F population or to a nonspecific response to chronic anemia. Comparison of the functional ability of Sl/Sld splenic fibroblasts to produce granulocyte/macrophage colony-stimulating activity with +/+ splenic fibroblasts demonstrated that there was no difference. Similar results were obtained for Sl/Sld and +/+ femoral fibroblasts. Analysis of CFU-F in W/Wv mice revealed an approximately 3-fold higher number of splenic CFU-F than in either +/+ or heterozygous (W/+ and WV/+) littermates. Since the anemia in W/Wv mice is attributed to a hemopoietic stem cell defect and that of the Sl/Sld mice is attributed to a microenvironmental defect, we suggest that the increased splenic CFU-F number in Sl/Sld mice is not specifically due to the microenvironmental defect, but is part of a general response to hemopoietic stress

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.